Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Canagliflozin Should Have Limitations Based On Renal Function, Panel Says

This article was originally published in The Pink Sheet Daily

Executive Summary

Several advisory committee members on both sides of a 10-5 vote voiced concern about using Janssen’s diabetes drug in patients with moderate renal impairment.


Related Content

FDA Panel To Weigh Dapagliflozin Bladder Cancer, CV Safety Questions
Eyes On Dainippon’s Phase III Stem Cell Cancer Drug – Japan Earnings Profiles
Cardiovascular Uncertainty Accompanies Canagliflozin To Advisory Panel
Bristol Signals Dapaglifozin’s Back On Track, Plans FDA Resubmission


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts